Best responses
| NIMES-ROC; Interim analysis | Total (n=158) | |
|---|---|---|
| Progression-free survival* (PFS); Overall survival** (OS) | months (95% CI) | 11.4 (10–14); nr (16.8-nr) |
| Best response during NIMES-ROC, n (%) | Complete response (CR) | 15 (9.5) |
| Partial response (PR) | 45 (28.5) | |
| Stable disease (SD) | 45 (28.5) | |
| Progressive disease (PD) | 32 (20.3) | |
| Not evaluable/Missing* | 21 (13,3) | |
| ORR (CR+PR); [95% CI] | 60 (38.0); [30.4–46.0] | |
| DCR (ORR+SD); [95% CI] | 105 (66.5); [58.5–73.8] | |
*Patients who have not died and do not have an assessment of disease progression are censored. **Patients who have not been reported as dead are included as censored. CI: confidence interval; DCR: disease control rate; nr: not reached; ORR: objective response rate.